1003316-26-4Relevant articles and documents
Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2)
Heidebrecht Jr., Richard W.,Chenard, Melissa,Close, Joshua,Dahlberg, William K.,Fleming, Judith,Grimm, Jonathan B.,Hamill, Julie E.,Harsch, Andreas,Haines, Brian B.,Hughes, Bethany,Kral, Astrid M.,Middleton, Richard E.,Mushti, Chandrasekhar,Ozerova, Nicole,Szewczak, Alexander A.,Wang, Hongmei,Wilson, Kevin,Witter, David J.,Secrist, J. Paul,Miller, Thomas A.
scheme or table, p. 2053 - 2058 (2009/11/30)
We report the preparation and structure-activity relationships of phosphorus-containing histone deacetylase inhibitors. A strong trend between decreasing phosphorus functional group size and superior mouse pharmacokinetic properties was identified. In add